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Abstract
Introduction
In radiation oncology treatment planning techniques and outcomes can differ from one institution
to the next. With knowledge-based planning (KBP) the experience of larger institutions could
help smaller institutions who may not have the opportunity to encounter certain types of cancer
cases. However, this scenario is only true if the KBP software is consistent with its algorithmic
output. This study investigates the validity and consistency of RP models from two different
radiation oncology institutions, and compare data to determine RP quality, and consistency in
planning prostate cancer cases.
Methods
In this retrospective study researchers at a Midwest cancer treatment institution, randomly
selected 50 previously treated prostate cancer cases from their database to form a Rapidplan (RP)
treatment estimation model (TEM). The 50 cases were used to “train” RP knowledge-based
learning software to the standards of an outside institutions model. The two TEM’s were
compared for variance, and 20 more cases were inserted into the TEM and evaluated to test
validity of the planning model overall.
Results
Results provided from the one-way ANOVA test supported the notion that a significant
difference between the mean dose volume histograms of both RP treatment estimation models
was not present. Pearson’s correlation also confirmed that positive correlations were present
between outside institution data points for PTV, bladder, rectum, and penile bulb and Midwest
institution datapoints for PTV, bladder, rectum, and penile bulb. Paired sample t-test, and
proximity matrix displayed significant similarities, and though there were significant differences
between the RP produced plans vs. physician approved plans, the proximity matrix supported a
significant association between the two versions of the 20 plans used for validation.
Discussion
To determine if a single RP model algorithm is robust enough to be applied between two
different institutions with similar treatment intents. We hypothesized that there must be a
relationship between the models produced at two different institutions. A series of statistical test
were performed to evaluate differences, similarities, correlations, and reliabilities of the data
pertaining to the two RP models under evaluation. Overall our findings indicated that there
weren’t many statistical differences, and there were consistently strong correlations between the
two institutions within our data. Literature reviewed results also confirmed common trends
between our finding and findings of past related studies.
Conclusion
Based on the finding of the results within this study we have concluded that the Varian algorithm
used for constructing RP models is robust enough to safety produce compatible plan outcomes
across different cancer treatment institutions. Moving forward follow-up research could be done
to explain why statistical differences are detected when correlations are strong, and reliability is
validated. Perhaps a deeper analysis of the nature of the algorithmic function could yield
conclusions.
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Introduction
Carcinoma of the prostate is the most prevalent cancer found in males. The prostate is a
walnut size gland which is located between the bladder and rectum and surrounds the urethra.
The prostate gland produces a substance that contributes to semen and is a functional component
of the male reproductive system1.Prostate cancer diagnosis rarely occurs in men under the age of
40. However, by age 50 it is more common for men to experience changes with the prostate2. In
the U.S., roughly 60% of men diagnosed with prostate cancer are 65 and older, and the average
age for prostate cancer is 662. Despite the strong correlation between age and prostate cancer,
there are also other risk factors associated with the development of prostate cancer as well. Other
known risk factors include race, genetics, and diet. The risk for developing prostate cancer is
highest for African American men than any other race. Risks are also higher than average for
individuals with a family history of prostate cancer3. Symptoms of prostate cancer could vary
amongst different individuals. However, difficulty urinating, hematuria (blood in urine), erectile
dysfunction, and painful ejaculation are common symptoms associated with prostate cancer4.
Most malignant tumors of the prostate are of the cell type of adenocarcinomas1.
Understanding the cell type is important because it helps professionals determine the stage and
grade of a tumor, which aids in diagnosing, determining treatment measures, and survival rates.
Like for many cancers, carcinoma of the prostate is characterized by the TMN staging system;
while Gleason score is used for grading of prostate tumors. TMN assess the extent of the
malignancy based on tumor size, metastases, and lymph node involvement. While Gleason score
is determined based on the level of cellular differentiation within the tumor1. Before health care
professionals can determine stage and grade they must first detect if the individual has prostate
cancer or not. For this purpose, many detection and screening methods are used. Each year men
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over the age of 50 are encouraged to have digital rectal exams (DRE), this is a diagnostic
examination in which a physician inserts his or her finger (digit) in the rectum to palpate for
abnormalities of the prostate. Also, there is an assessment of the prostate specific antigen (PSA)
which is a specific protein in the blood that is produced by the prostate. The normal PSA value is
4ng/mL, but higher PSA values may by acceptable based on age. Nevertheless, when this PSA
value is exceeded in the blood, it could indicate development or escalation of malignancy
associated with the prostate. The PSA value may also have an impact on the type of treatment
one may receive as well5. Primarily Transrectal ultrasound (TRUS) guided biopsy has been the
standard for prostate cancer diagnosis. Much research has been conducted to determine whether
diagnosis through transrectal ultrasound guided scans are accurate enough to result in the
elimination of biopsy. To be less invasive transrectal magnetic resonance imaging is a newer
technique also used for evaluation6. As a result of findings from these examinations and imaging
studies the stage of disease is determined. Classified by the American Joint Committee on
Cancer (AJCC) TNM stages 1-4 occurs under different circumstances. T1 occurs when well
differentiated adenocarcinomas found via fine needle biopsy, or by high PSA values. To classify
as T1 typically less than 5 % of tissue show abnormality. T2 occurs with tumors in the prostate
that are palpable and encapsulated. T2 is usually detected by DRE. T3 occurs in tumors that are
more locally extensive, beyond the edges of the prostate to surrounding structures such as the
seminal vesicles.; Typically, with poorly differentiated cells. T4 occurs when larger tumors are
fixed to the pelvic wall or invade adjacent structures such as the bladder or rectum1. N1 occurs
when there is nodal involvement, and M1 occurs when there is metastases, which varies based on
location7. The Gleason Score is obtained when prostate cancer is found on a biopsy. The Gleason
score is determined by how abnormal cells look under a microscope. During pathological
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grading the primary, and secondary tumor grades are added together to get the Gleason score,
which ranges from 2-101. Usually prostate cancers that are well-differentiated are classified with
scores of 6 or lower, while moderately differentiated cells tend to have a score of 7, and 8-10 are
for poorly-differentiated cells5.
Prostate cancer is treated based on stage and grade. T1, depending on the grade of the
disease, may not require any treatment until disease becomes a clinical issue1. Depending on the
grade and extent of tumor, T2 may require prostatectomy alone. In cases with patients who have
stage T3, external beam radiation therapy (EBRT), typically with hormonal therapy, is the
standard of practice1. In addition, some individuals with T3 may be eligible for Low Dose Rate
(LDR) brachytherapy via prostate seed implants (PSI), which is the process of physically
implanting radioactive seeds into the prostate through the perineum1. Though rarely seen,
patients may undergo concurrent in T3-T4 stages of cancer as well if there is no response to
hormonal therapy, and/or if disease has rapidly spread outside the prostate1.
Favorably, prostate cancer patients have received the most dividends over the past decade
from the progression of technology, especially with the emergence of IMRT and VMAT8. This is
primarily related to the fact that dose conformity around the prostate has drastically increased.
As a result of this dose conformity, there is a reduction in toxicity of critical structures which has
aided in the decrease of secondary malignancies, as well as a better prognosis8 According to the
National Cancer Institute (2019) for prostate patients with radiation therapy as their primary
treatment measure, all stages of prostate cancer combined had an overall five-year survival rate
of over 98%4. The increase in 5-year survival rates for prostate patients has been associated with
higher quality of radiation therapy treatments, which are made possible by technological
advancements seen in radiation therapy over the last decade9.
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Due to the success of radiation therapy, radiation oncology has become a more widely
adopted and effective cancer treatment method9. Today, radiation therapy leverages advanced
and complex technologies for more advantageous outcomes. As progression occurs within
radiation oncology, medical dosimetrists are challenged to adhere to more robust standards. A
medical dosimetrist, also known as the “treatment planner”, is a member of a radiation oncology
team, responsible for planning optimal dose delivery to tumor volumes while allowing the least
possible dose to healthy organs. The medical dosimetrist maintains a delicate balance between
delivering the prescription the physician has written while ensuring the patient will not lose
healthy organ function10.
In modern radiation therapy planning, medical dosimetrists commonly utilize intensity‐
modulated radiation therapy (IMRT) for prostate cancer. IMRT is a radiation therapy dose
delivery technique which uses the multi-leaf collimators in the head of a linear accelerator to
adjust the intensity of the radiation beam to match the precise contours of a tumor and minimize
the damage to surrounding tissue11. Furthermore, volumetric-modulated arc therapy (VMAT) is
another treatment technique used for prostate cancer treatment. VMAT delivers radiation by
rotating the radiation machine through one or more arcs while radiation is continuously
delivered. VMAT allows doctors to treat complex cancers while minimizing exposure to
surrounding healthy tissue. This is accomplished primarily through the variation of dose rate at
every angle of the arc11. With the increasing prevalence of treatment techniques such as IMRT
and VMAT radiation therapy treatment, planners are better able to maximize tumor control while
minimizing toxicity to normal structures12.
In addition to the prominence of IMRT and VMAT techniques, the next innovation of
knowledge-based planning (KBP) looks to advance treatment planning even further. KBP
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software applies the knowledge it has learned from model plans input into the software to
generate plans that can be applied to new cases. It uses an automated approach that involves the
use of algorithms to predict desirable outcomes for treatment plans before they are corrected by
treatment planners and physicians to become deliverable plans13. Though KBP software, such as
Varian’s RapidPlan (RP), was developed for multiple intents, one of the best characteristics of
RP is that knowledge-based models can be shared between institutions. This is especially
beneficial for smaller institutions who may not treat as many cases and therefore may not
produce an optimal quality plan due to lack of experience. Using the KBP, these institutions
would be able utilize a model from larger and more experienced institution to aid them in
treatment planning.
When KBP first emerged during the early 2010s, researchers attempted to validate the
feasibility of KBP systems by comparing plan quality of RP generated plans to those of
physician approved plans produced by a medical dosimetrist. In a particular study, a group of
researchers stated that, “On average, the new knowledge‐based plan is capable of achieving very
comparable planning target volume coverage as the original plan, to within 2% as evaluated”14
This statement supports the legitimacy of KBP systems, such as RP, in a clinical setting.
By 2015, the knowledge of RP and other KBP systems had grown within the field of
radiation oncology. A literature review published in 2019 summarizes the approaches of 73
different articles published on RP or other KBP software between 2011-201813. In this literature
review, it was concluded that across the 73 studies they aimed to validate KBP software to plan
different anatomical cancer sites. They found that the KBP methods were generally equivalent to
expert level planners in terms of plan quality, but preliminary results indicated that they were
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significantly more efficient. These results suggested that clinical application of KBP to some
cancer types such as prostate was very achievable13.
In analyzing previous studies done on KBP systems, it was recognized that there were
correlations amongst these types of studies. Some of the articles have different methods or the
focus of the article may be geared toward validation of knowledge-based planning for treatment
of certain organs. Nevertheless, it has been frequently concluded that in these studies the KBP
software often generated optimal treatment plans regardless of which structure was being treated.
Based on the conclusion of other KBP studies, the researchers of this study expect RP to be able
to plan prostate cancer cases adequately. Contrary to those studies, the researchers of this study
aim will be to focus on the similarities and differences of RP generated models for prostate
cancer from two different institutions. The conclusion of this study will help determine the level
accuracy for plan outputs when sharing RP models across different organizations.
In this retrospective study, the principle researcher compared RP models for prostate
cancer between two different radiation oncology institutions. An outside institution RP prostate
model was compared to the RP prostate model produced at a Midwest institution. Then,
comparison was conducted amongst the two models DVH’s, and treatment variables evaluating
the possibility of variance. Following this, the RP prostate model that was initially created was
be used to plan separate prostate cases, which were then compared to physician approved plans
produced by faculty treatment planners. In this study, it is hypothesized that there will be a
significant relationship of similarity between the outside institution prostate cancer model and
the Midwest institution prostate cancer model, thus, affirming the feasibility of sharing RP
models amongst different institutions.
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Null hypothesis (Ho): There is not a significant relationship between the outside
institution prostate cancer model and the Midwest institution prostate cancer model.
Alternating hypothesis (Ha): There is significant relationship between the outside institution
prostate cancer model and the Midwest institution prostate cancer model.

Methods
Overview
This retrospective study used a Rapidplan (RP) prostate model produced by an outside
institution as a template for constructing and validating an initial RP prostate model made at a
Midwest institution. The Midwest institution RP prostate model included 50 randomly selected
physician approved prostate carcinoma plans from previously treated patients within their
database. After the model was trained based on the treatment planning parameters of the 50
cases, researchers at the Midwest institution compared their model to the outside institutions
model to see if there were any significant differences between the two models, as well as a
significant relationship between the two models. Comparison was done by assessing the PTV,
and organs at risk involved in the prostate cancer plans and seeing how much the variables
correlated with and deviated from each other, Following this comparison, the Midwest cancer
treatment institution input another 20 physician approved plans into their trained model to
compare the RP produced plans to the original plans prepared by the Midwest institutions
dosimetrist.
Patient selection
This retrospective study began initially with 100 previously treated prostate cancer cases
which were retrieved from a Midwest cancer treatment institution’s database. All cases were
physician approved based on the study criteria. These cases were selected at random focusing on
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patients that were treated between 2017 and 2019. Inclusion criteria into the initial 100 were
males over the age 18, who received treatment to the prostate only (not to include pelvic lymph
nodes) with IMRT or VMAT planning techniques. The age of the subjects ranged from 35 to 81,
with the median age range being around 63.8 years. Of these initial 100 cases the first 50 cases
were selected to construct the RP Treatment Estimation Model (TEM). After the Midwest
institutions model was trained and compared to the outside institutions model, 20 separate cases
were retrieved from the 100 cases initially collected and used to test the validity of the RP
knowledge-based planning software overall. The remaining 30 cases from the initial 100, were
used to replace outlier cases that may arise as confounding variables and falsely impact the
calculations of the TEM.
IRB
This retrospective study was governed by a “blanket IRB continuation research report”
provided by the radiation oncology department of the Midwest cancer treatment institution. This
IRB was approved on 01/18/2019 by the hospitals internal review board, and covered all
research conducted within the radiation oncology department at the Midwest institution. A Data
Use Agreement (DUA) was also submitted to the Midwest Institution. The DUA outlined the
purpose, methods, and actions taken to protect personal health information (PHI) and comply
with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). After the
population was selected, personal identifiers were destroyed, and data was anonymized using
hospital software within the computer system. All patient information was destroyed using
software that is capable of destroying and anonymizing PHI. This retrospective study presents no
more than minimal risk to patient privacy. The study was also approved by the Grand Valley
State University (GVSU) Institutional Review Board (IRB) under the exempt review category.
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Training the Treatment Estimation Model
Training the Treatment Estimation Model (TEM) consisted of a 4-step process. First, the
principal researcher created a DVH Estimation Model Container. This container was used to
deploy all the cases used for training the model. Second, a sample of 50 prostate cases were
inserted into the DVH Estimation Model Container. These 50 cases were retrieved from a cohort
of 100 randomly selected cases initially collected at the start of the study. Third, the individual
DVH’s for each of the 50 cases were evaluated by the RP software. This evaluation ensured that
there were no underlying outliers amongst the 50 cases within the Estimation Model Container.
Outliers were identified based how much they deviated from the parameters manually inputted
into the DVH model configuration chart, and were determined to be an outlier based on the
number of standard deviations from the mean. Software calculations request 99.8% of the data
points for all organs, and treatment volumes to be within 4 standard deviations to be considered
valid as seen in figure 1. Next, optimization objectives, normal tissue objectives (NTO), and
smoothing parameters were set to mirror that of the outside institution. Finally, after all data
points were deemed acceptable and free of statistical outliers the principal researcher employed
the “train” function of the knowledge-based learning software which allowed RP to perform it
algorithmic calculations to produce an official RP model that had learned from the 50 inserted
cases. The RP model was then published and open to calculate new prostate cancer cases.
Validation of Rapid Plan Model
After the RP model was completely trained based on the treatment planning parameters
of the 50 approved prostate cases inserted into the training model container, the RP model was
ready for validation. The first step of validation was to select a new cohort of 20 prostate cancer
11

cases. These identical prostate cancer cases that originated as physician approved plans were replanned using the RP model at the Midwest institution, researchers had to compare the new plans
generated from the RP model to the corresponding original physician approved plan. After
comparing the differences between the RP produced plans, and the original physician approved
plans, researchers then observed whether the parameters of the radiation prescription were met
for the RP produced plans to determine the validity of the Midwest RP model that was set by the
parameters of an outside institution.

Results
Dose Volume Histogram Outliers
For this study the principle researcher at the Midwest institution used the DVH
estimation model to identify outliers and replaced them with cases that were closer to the DVH
of the outside institutions model. As illustrated in Figure 2, four outliers were identified. These
four PTV datapoints were removed from the DVH plot and replaced with 4 other datapoints from
separate cases that better fit the model DVH. Figure 3 displays the estimation model DVH plot
that contained the new PTV datapoints, and this dataset was used to train the TEM. All other
datapoints were within 4 standard deviations of the parameters inputted into the software and set
to mimic the outside institutions model.
Treatment Estimation Model comparison
For TEM comparison, an evaluation was done to assess how much the Midwest
institution’s TEM differed from the outside institution’s TEM. A comparative graph was made to
illustrate the difference between the two models, this was based on the mean DVH for both
models as seen in figure 4. A one -way ANOVA was also conducted for this comparison. Each
of the 50 datapoints had a p < .05, meaning that there was not a significant difference between
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the outside institutions model and the Midwest institution’s model for the PTV (.009), bladder
(.045), rectum (.048), and penile bulb variables as seen in Table 1. In measuring the relationship
between the two TEMs data points, a Pearson’s correlation test was performed for each variable
amongst the two groups, as displayed in Table 2. Figures 5,6,7,8 depicts the correlation of each
variable between both institutions’ TEMs. Lastly, a Chi-Square test was performed to test the
strength of the relationship between the variables of the two models, and due to the significance
being represented by all of the p <.05, a significant relationship between the RP model from the
outside institution and the Midwest institution is implied as seen in Table 5.
Analysis of RapidPlan model validation
To examine the difference between the plans produced by the RP model, and
corresponding physician approved plans, a paired t-test was performed as displayed in Table 3.
Next a proximity matrix was conducted to measure similarity between the RP produced prostate
cases and the predicted outcomes of the RP algorithm as seen in Table 4.

Discussions
Review of Results
Results initially revealed that when the researchers first removed outlying data points that
there were four outliers within the PTV DVH that were used to train the Midwest TEM. These
data points were removed because they were greater than four standard deviations from the
mean; this was done based on the outside institution’s model parameters. After cleaning up the
raw data, the researchers conducted statistical testing that would aid in the investigation of the
relationship between the outside and the Midwest institution’s RP model.
To start, a comparative DVH was prepared as a visual indicator between the outside
institution and Midwest institution, to identify how much these two models differed and related
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to each other. Next, to determine if any variance was present between the two TEMs, a one-way
ANOVA test was done on the two models. Based on the p-values of the PTV, bladder, rectum,
and penile bulb all being less than .05, significance was indicated. This meant that there was no
significant difference between the two models. Also, the one-way ANOVA contained an F ratio
score, measuring the joint variance of all variables across each group. When these variables are
closer to zero than one, it indicates that all the variables from the outside institution do not
significantly differ from the variables of the Midwest institution.
To further investigated the relationship between the two models, Pearson’s correlation
was done using the data points of each variable from both institutions RP model DVHs. With
Pearson’s correlation, the closer the correlation coefficient value is to 1, the stronger the
correlations between variables. In statistics, any correlation greater than 0.50 usually depicts a
strong correlation. Data points from both institutions’ DVH variables (e.g., PTV’s, bladder,
rectum, and penile bulb) were compared to the mean dataset from the outside institution’s RP
model. As expected, the outside institution’s data points matched perfectly to the datasets from
its own institution’s model. And the same can almost be said about the Midwest institution.
Based on the findings from the Pearson’s correlation, the Midwest variables of PTV (r =.97),
bladder (r =.81), rectum (r = .74), penile bulb (r = .89) all had correlation coefficients greater
than .50. This further indicates that a relationship does exist between the two models from both
institutions.
As the relationship between the two models continued to be investigated, , Chi-Square
test was conducted to assess the association between the variables of the two RP models. To
perform this test, 100 cases, 50 from each institute, were compared. The data was compiled in
SPSS output and represented as individual entities. These entities were used for the Chi-Square
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test. As seen in Table 5, the Chi-Square sig value was .048 which is < .05 supporting statistical
significance, and as a result further affirming that an association does exist between the Midwest
and outside institution’s models.
In this study, the researchers also attempted to test the validity of 20 prostate cancer plans
produced by the RP algorithmic software in the RP model. A before and after comparison of the
Midwest institution’s physician approved plans versus the RP produced plans was done by
performing a paired sample t-test. The paired t-test revealed that a significant difference was
present between the RP produced plans and original corresponding physician approved plans, as
indicated by the .017 p value. However, in examining Table 3, , it would be noted that the
correlation coefficient is deemed as .998, with .000 p value indicating a significant correlation
between the original physician approved plans and the plans produce by the RP model. After
review of the result with professionals at Grand Valley State University statistics department, it
was concluded that the paired t-test displayed a significant difference between the two plan types
because the model was built from the outside institution’s model, while the original plans were
created by dosimetrist to meet the standards of the physician’s radiation prescription at the
Midwest institution. In other words, the RP model cases were planned to the standard of the
outside institution, while the original corresponding plans were planned to the standards of the
treatment prescription from the Midwest institution. Two different planning parameters
explained why a significant difference was detected within the paired t-test. Nevertheless, the
strong correlation depicted in Table 3 also indicated that though the data points showed a
significant difference, there still was a similar relationship between the outcomes of two groups
as represented by the high correlation coefficient.
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In addition to the paired t-test and correlation test, SPSS was used to perform another
comparative measure of similarity by employing the Proximity Matrix. According to SPSS, the
Proximity matrix is a tool used to test the distance between pairs of cases or pairs or variables.16
When examining the relationship between the RP produced plans and the corresponding original
plans, the proximity matrix was used to get a more robust comparison and to further investigated
the relationship between RP produced prostate plans, and their original physician approved
counterparts. Like the Pearson’s correlation the closer the value is to 1 the stronger the similarity
is amongst the variables. In Table 4, the proximity matrix shows the similarity that each variable
has with each other. The findings from this chart shows that outcomes of the same variables
between the two institutions are identical, with a 1 representing the similarity between outcomes.
Based on the finding of this data the assumptions of a relationship existing between the RP
produced plans and their corresponding physician approved plans are very reasonable.
Cross-reference of results from literature reviewed studies
Within this retrospective research study, multiple statistical tests were conducted to
evaluate differences, similarities, correlations, and reliabilities of the data pertaining to the two
RP models under evaluation. To truly draw accurate conclusions and to test the hypothesis, these
tests were examined as the foundation for further escalation of research on KBP software
capabilities. The findings of this study were validated by similar findings present in other studies
that evaluated the validity of KBP software capabilities. In this study, it was revealed that there
was a significant difference when comparing the RP model produced plans with the original
physician approved plans., meaning that the two model were recognized as not being completely
the same. In a study entitled “RapidPlan knowledge-based planning: iterative learning process
and model ability to steer planning strategies”, the researchers came to a similar conclusions. By
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assessing the linear regression of two different RP models, they concluded that there too was a
significant difference between the two model especially when the algorithm of RP attempted to
reduce dose for parallel and series organs. However, like the findings of this study, Fogliata et al.
(2019) indicated they saw an increase in correlation between both plans. According to Fogliata et
al. the different models within their study were able to yield similar plans according to each
original strategy17. The similarities between the finding in this retrospective study, as well as the
finding displayed by Fogliata and colleagues in 2019, shows that even though the system’s
planning may differ based on the intent that the software is striving to meet, it still has the
capabilities to produce the desired outcomes that it is commanded to reach. It would be
beneficial if more research is done to further asses why significant differences occur when strong
correlations, and compatible results are yielded between different RP models.

Conclusion
Within this study, the researcher elaborated on the prominence of prostate cancer within
radiation oncology and how new innovations such as RP could be beneficial in treating these
types of cancers as well as more complex cases across different institutions. Within this study,
the researchers at a Midwest institution used previously treated prostate cancer cases to further
test the robustness of RP algorithmic capabilities. A RP model was created to mirror that of an
outside institution’s RP model, and treatment estimation models were legitimized and compared
between both institutions. Multiple statistical test was conducted to evaluate differences,
similarities, correlations, and reliabilities of the data pertaining to the two RP models under
evaluation. Within the results section, the findings depicted that there was a consistent
relationship between the Midwest institution’s model and the outside institution’s model. This
was confirmed by the One-way ANOVA, Pearson’s correlation, and other forms of descriptive
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statistics. Ultimately, these findings have led the principle researcher at the Midwest institution
to reject the null hypothesis, which states that there is not a significant relationship between the
outside institution prostate cancer model and the Midwest institution prostate cancer model. By
rejecting the null hypothesis, the researcher can conclude that, as predicted there is a relationship
between the two models. This relationship indicates that the algorithmic capabilities of RP can
be considered valid, consistent, and reliable. Therefore, the feasibility of different institutions
utilizing one another’s RP models to combat the lack of experience or promote standardization is
acceptable and safe for patients.
Overall this study underwent different processes to determine if the RP KBP software
could continue its groundbreaking trends and be viewed as a legitimate option for sharing
planning experience between different institutions. Based on the statistical findings within this
study, such as the presence of a strong correlation coefficient amongst all output variables and p
values < .05 for the one way ANOVA it has been revealed that a significant relationship does
occur between the Midwest Institutions RP model and the outside institutions RP model.
Furthermore, the principal researcher within this study rejected the null hypothesis which states
that there is not a significant relationship between the outside institution prostate cancer model
and the Midwest institution prostate cancer model. It is anticipated that this study can contribute
to the forum of KBP related research, spark inquisitive conversations and research that would
broaden knowledge of how innovations such as RP can benefit more patients undergoing
radiation therapy treatments. Moving forward follow-up research could explain why statistical
differences are detected when correlations are strong, and reliability is validated when comparing
variables from two or more RP models. Perhaps a deeper analysis of the nature of the
algorithmic function used by Varian could yield valid conclusions.
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Figure 1. Varian Rapid Plan 15.5
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Figure 2. Midwest Institution’s Initial PTV Plot
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Figure 3. Midwest Institution’s Corrected PTV Plot
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(OI = Outside Institution, MW = Midwest Institution)
Figure 4. Comparative TEM of mean DVH’s for OI and MW RP models
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Figure 5. Pearson’s Correlation (Midwest vs. Outside Institution PTV)
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Figure 6. Pearson’s Correlation (Midwest vs. Outside Institution Bladder)
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Figure 7. Pearson’s Correlation (Midwest vs. Outside Institution Rectum)
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Figure 8. Pearson’s Correlation (Midwest vs. Outside Institution Penile Bulb)
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Table 1. One-way ANOVA (SPSS20)
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Table 2. Pearson’s Correlation Test (SPSS 20)
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Table 3. Paired Samples & Pair t-test

Table 4. Paired Samples Correlations

Tables 5. Paired Samples T-Test
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Table 6. Proximity Matrix
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Chi-Square Tests
Value

df

Asymp. Sig. (2-sided)

24.000a

50

.048

33.271

50

.724

Linear-by-Linear Association

.007

1

.933

N of Valid Cases

100

Pearson Chi-Square
Likelihood Ratio

Table 7. Chi Square
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